Long-term safety of antibodies for IBD maintenance
Part of Digestive system clinical trials.
This trial is testing long-lasting antibodies given alone or in combinations to keep IBD under control over the long term. It's for people who already did well in the initial study and want to continue treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already taken part in the earlier SPY123-201 study and either finished it, or needed extra treatment because your symptoms weren't improving.
- You cannot have been stopped from the earlier study due to side effects or other safety reasons.
- You cannot be taking strong immune-suppressing drugs (like methotrexate, cyclosporine, or other biologics) right now.
- You must not have developed any new serious health issues (like a new infection, heart problem, or cancer) since starting the study.
- You must not have an infection that needs antibiotics or antiviral treatment at the start of this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests new long-acting antibodies, given alone or in combination, for people with moderate to severe ulcerative colitis. The goal is to see if these treatments can help reduce inflammation and improve symptoms.
This study tests a new medication called BI 3032950 for people with ulcerative colitis who have already tried other advanced treatments (biologics or targeted therapies) that didn't work well enough or caused problems. The goal is to see if the new drug is safe and helps control inflammation in the colon.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This trial tests whether “treat-to-target” care—guided by regular symptom checks, telemonitoring, and patient education—works better than standard follow-up when starting adalimumab for ulcerative colitis. It aims to help control inflammation more effectively and reduce flare-ups.
This study is for people who already completed 52 weeks of treatment with TAK-279 for ulcerative colitis or Crohn's disease and saw improvement. It gives them the option to continue the medication long-term to see if the benefits last.
This study follows adults with Crohn’s disease or ulcerative colitis to compare the long-term safety of ustekinumab against other biologic medicines. It may help show how safe these treatments are over time, using medical records.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.